<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357654</url>
  </required_header>
  <id_info>
    <org_study_id>PRO20140001128</org_study_id>
    <nct_id>NCT02357654</nct_id>
  </id_info>
  <brief_title>GnRH for Luteal Support in IVF/ICSI/FET Cycles</brief_title>
  <official_title>GnRH for Luteal Support in IVF/ICSI/FET Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Reproductive Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Reproductive Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days
      after fertilization. For a successful pregnancy to take place, that embryo must then implant
      in the properly primed and staged endometrium, which subsequently must continue to develop to
      accommodate the growing and maturing embryo and then fetus. This process is normally
      regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has
      been found that after IVF additional support for the endometrium with progesterone improves
      implantation and subsequent live birth rates in IVF cycle . Recent data has shown that
      additional supplementation with a single administration of a GnRH agonist around the time the
      time of embryo transfer may further enhance these rates .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth per transfer</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rates</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rates of OHSS</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>GnRH agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH</intervention_name>
    <description>single shot of GnRH agonist</description>
    <arm_group_label>GnRH agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years
             old.

        Exclusion Criteria:

          -  day 3 transfers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter G McGovern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers-New Jersey Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter G McGovern, MD</last_name>
    <phone>201-288-6330</phone>
    <email>mcgovepg@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Reproductive Associates</name>
      <address>
        <city>Hasbrouck Heights</city>
        <state>New Jersey</state>
        <zip>07604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter G. McGovern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD009154. doi: 10.1002/14651858.CD009154.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD009154.</citation>
    <PMID>21975790</PMID>
  </reference>
  <reference>
    <citation>Oliveira JB, Baruffi R, Petersen CG, Mauri AL, Cavagna M, Franco JG Jr. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol. 2010 Sep 8;8:107. doi: 10.1186/1477-7827-8-107. Review.</citation>
    <PMID>20825643</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>March 10, 2018</last_update_submitted>
  <last_update_submitted_qc>March 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

